M Niedergethmann

Summary

Affiliation: University of Heidelberg
Country: Germany

Publications

  1. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
  2. ncbi Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection
    M Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany
    Int J Pancreatol 28:31-9. 2000
  3. doi Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, Faculty of Medicine Mannheim University of Heidelberg, Mannheim, Germany
    World J Surg 32:2253-60. 2008
  4. pmc Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model
    M Niedergethmann
    Faculty of Medicine Mannheim, Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim 68135, Germany
    Br J Cancer 97:1432-40. 2007
  5. ncbi Early and enduring nutritional and functional results of pylorus preservation vs classic Whipple procedure for pancreatic cancer
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, 68135, Mannheim, Germany
    Langenbecks Arch Surg 391:195-202. 2006
  6. ncbi Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany
    Pancreas 29:204-11. 2004
  7. ncbi Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, 68135 Mannheim, Germany
    Am J Surg Pathol 26:1578-87. 2002
  8. ncbi [Monstrous, retroperitoneal liposarcoma--a case report]
    M Niedergethmann
    Chirurgische Klinik, Universitatsklinikum Mannheim, Fakultät für Klinische Medizin Mannheim, Universitat Heidelberg
    Swiss Surg 7:32-5. 2001
  9. ncbi Rare indications for a Kausch-Whipple procedure
    M Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Eur J Surg 167:115-9. 2001
  10. ncbi [Detection of micrometastases after curative resection for ductal adenocarcinoma of the pancreas]
    M Niedergethmann
    Chirurgische Klinik, , , Germany
    Zentralbl Chir 126:917-21. 2001

Detail Information

Publications22

  1. pmc A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
    Helmut Friess
    Department of General Surgery, University of Heidelberg, Heidelberg, Germany
    BMC Cancer 6:285. 2006
    ..In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer...
  2. ncbi Angiogenesis and cathepsin expression are prognostic factors in pancreatic adenocarcinoma after curative resection
    M Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany
    Int J Pancreatol 28:31-9. 2000
    ..g., cathepsin B (CTSB) and L (CTSL), are factors of prognostic relevance, we investigated their expression in patients with long- and short-term survival after curative resection (RO) because of pancreatic adenocarcinoma...
  3. doi Outcome of invasive and noninvasive intraductal papillary-mucinous neoplasms of the pancreas (IPMN): a 10-year experience
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, Faculty of Medicine Mannheim University of Heidelberg, Mannheim, Germany
    World J Surg 32:2253-60. 2008
    ..Based on a two-center database, we reevaluated histopathological findings, clinicopathological pattern, predictive markers for malignancy, and outcome...
  4. pmc Gene expression profiling of liver metastases and tumour invasion in pancreatic cancer using an orthotopic SCID mouse model
    M Niedergethmann
    Faculty of Medicine Mannheim, Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim 68135, Germany
    Br J Cancer 97:1432-40. 2007
    ..Overrepresentation analysis secures a good and fast overview about the significantly regulated genes and can assign genes to certain pathways. These marker genes can be related to the apoptotic cascade, angiogenesis and cell interaction...
  5. ncbi Early and enduring nutritional and functional results of pylorus preservation vs classic Whipple procedure for pancreatic cancer
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, 68135, Mannheim, Germany
    Langenbecks Arch Surg 391:195-202. 2006
    ..The aim of this study was to compare nutritional and functional results of the different techniques in a retrospective evaluation and prospective cohort study...
  6. ncbi Prognostic impact of cysteine proteases cathepsin B and cathepsin L in pancreatic adenocarcinoma
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany
    Pancreas 29:204-11. 2004
    ....
  7. ncbi Prognostic implications of routine, immunohistochemical, and molecular staging in resectable pancreatic adenocarcinoma
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, 68135 Mannheim, Germany
    Am J Surg Pathol 26:1578-87. 2002
    ..The described PCR method clearly determines subgroups of patients after curative resection with early recurrence and poor survival and could therefore enrich the pathologic examination...
  8. ncbi [Monstrous, retroperitoneal liposarcoma--a case report]
    M Niedergethmann
    Chirurgische Klinik, Universitatsklinikum Mannheim, Fakultät für Klinische Medizin Mannheim, Universitat Heidelberg
    Swiss Surg 7:32-5. 2001
    ..Since neoadjuvant and adjuvant therapy as well as intraoperative radiotherapy failed to prove prognostic value, curative resection remains the main treatment for primary and recurrent liposarcomas...
  9. ncbi Rare indications for a Kausch-Whipple procedure
    M Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Eur J Surg 167:115-9. 2001
    ..To find out whether the Kausch-Whipple operation is adequate for the cure of rare tumours of the pancreatic head...
  10. ncbi [Detection of micrometastases after curative resection for ductal adenocarcinoma of the pancreas]
    M Niedergethmann
    Chirurgische Klinik, , , Germany
    Zentralbl Chir 126:917-21. 2001
    ..Routinely assessed, this method is able to detect MRD and could enrich the pathological examination, in order to determine prognostic relevant subgroups of patients...
  11. ncbi Postoperative complications of pancreatic cancer surgery
    M Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Minerva Chir 59:175-83. 2004
    ..Pancreaticoduodenectomy can be a safe procedure in experienced institutions, where the whole medical team is able to diagnose and treat these complications at any time...
  12. ncbi [Ultrafast magnetic resonance tomography changes the standard in pancreas diagnosis]
    A Richter
    Chirurgische Klinik, Universitatsklinikum Mannheim, Klinische Fakultät der Universität Heidelberg, Mannheim
    Chirurg 72:697-703. 2001
    ..Since the introduction of MRI, including imaging of the hepato-pancreatic duct system (MRCP) and 3D-MR angiography (3D-MRA), new pancreatic diagnostic procedures have been developed...
  13. ncbi Benefit of venous resection for ductal adenocarcinoma of the pancreatic head
    Mark Hartel
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany
    Eur J Surg 168:707-12. 2002
    ..To find out whether there is any benefit from venous resection during pancreaticoduodenectomy for ductal pancreatic adenocarcinoma...
  14. ncbi Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience
    Axel Richter
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Theodor Kutzer Ufer, 68167, Mannheim, Germany
    World J Surg 27:324-9. 2003
    ..We concluded that surgical treatment is "as good as it gets," as extended techniques have not proved to produce better results...
  15. ncbi [Elective colon resection in Germany. A survey of the perioperative anesthesiological management]
    T Hasenberg
    Chirurgische Universitatsklinik, Klinikum Mannheim gGmbH, Mannheim, Deutschland
    Anaesthesist 56:1223-6, 1228-30. 2007
    ..This leads to an improved and accelerated recovery and avoids perioperative complications. This survey focuses on the extent and use of such concepts in Germany...
  16. ncbi High expression of vascular endothelial growth factor predicts early recurrence and poor prognosis after curative resection for ductal adenocarcinoma of the pancreas
    Marco Niedergethmann
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany marco niedergethmann chir ma uni heidelberg de
    Pancreas 25:122-9. 2002
    ..A second goal was to characterize the VEGF-producing cells and the subcellular distribution...
  17. doi Randomized controlled trial: comparison of two surgical techniques for closing the wound following ileostomy closure: purse string vs direct suture
    N Dusch
    Department of Surgery, University of Heidelberg, Mannheim, Germany
    Colorectal Dis 15:1033-40. 2013
    ..Secondary end-points were cosmetic outcome [using two validated scales: the Patient and Observer Scar Assessment Scale (POSAS) and the Body Image Questionnaire (BIQ)] and the influence of other factors on the SSI rate...
  18. doi [Significance of drains in surgery]
    M Niedergethmann
    Chirurgische Universitatsklinik, Universitatsmedizin Mannheim, Mannheim, Germany
    Chirurg 82:1079-84. 2011
    ..The available data suggest that in most cases a prophylactic drainage can be avoided. In addition, drains may lead to increased morbidity and higher treatment costs...
  19. ncbi Resection for cancers of the pancreatic head in patients aged 70 years or over
    Axel Richter
    Department of Surgery, University Hospital Mannheim, University of Heidelberg, Germany
    Eur J Surg 168:339-44. 2002
    ..To find out if resections of cancers of the head of pancreatic are justified in patients over the age of 70 years...
  20. doi [Open abdomen 2009. A national survey of open abdomen treatment in Germany]
    F Herrle
    Chirurgische Klinik, Universitatsmedizin Mannheim, Medizinische Fakultat Mannheim, Universitat Heidelberg, Theodor Kutzer Ufer 1 3, Mannheim, Germany
    Chirurg 82:684-90. 2011
    ..Open abdomen (OA) treatment has been established worldwide. This survey examines the current status of OA treatment in Germany...
  21. doi Prediction of anastomotic leakage after pancreatic head resections by dynamic magnetic resonance imaging (dMRI)
    Dietmar J Dinter
    Department of Clinical Radiology and Nuclear Medicine, University Hospital Mannheim, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany
    J Gastrointest Surg 13:735-44. 2009
    ..In order to identify risk factors and to assess the role of pancreatic dMRI, a cohort of patients was retrospectively reviewed...
  22. ncbi Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial
    Helmut Oettle
    Department of Medical Oncology and Hematology, Charite School of Medicine, Campus Virchow Klinikum, Berlin, Germany
    JAMA 297:267-77. 2007
    ..The role of adjuvant therapy in resectable pancreatic cancer is still uncertain, and no recommended standard exists...